Anti-RBD-4 antibody (Casirivimab)

Reference: PTXCOV-A552
Product nameAnti-RBD-4 antibody (Casirivimab)
SpeciesHuman
Expression systemMammalian
Molecular weight150kDa
Purity85%
BufferPBS, pH7,5
FormLiquid
Delivery conditionDry ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteogenix
ApplicationsELISA,WB
Aliases /SynonymsREGN10933
ReferencePTXCOV-A552
Related ProductsRBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant,RBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant,SARS-CoV-2 RBD of Spike protein, K417N, E484K, N501Y – B.1.351 lineage – SA Beta Variant,SARS-CoV-2 RBD of Spike protein, E484K
NoteFor research use only. Not suitable for in vitro diagnostic and human use.
IsotypeIgG1
ClonalityMonoclonal Antibody
TargetRBD domain- SARS-CoV2 Spike protein for first type and variants (PX-COV-P046, PX-COV-P052, PX-COV-P053, PX-COV-P056)

General information on Anti-RBD-4 antibody

The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the most important target for the design of novel therapies for COVID-19. The development of antibodies that can target this specific area can be done in vivo, which is a time-consuming in vitro process or which can take advantage of the flexibility of visualization technologies such as pH age visualization. Anti-CoV-RBD antibody was developed by pHa to visualize the extensive library of COVID-19 (LiAb-SFCOVID-19 ™) antibodies against SARS-CoV-2 RBD. Whereas generation of antibodies based on pH age does not require animal immunization or the use of immunogenic antigens, only small RBD proteins are used to isolate specific RBD ligands from the LiAb-SFCOVID-19 TM library. Furthermore, since the library is composed of immune libraries from COVID-19 patients, it possesses the largest and most important biological antibodies with important neutralizing activities.
Therefore, this specific antibody is a fully human immunoglobulin in IgG format. The ELISA (Enzyme-linked immunosorbent assay) test was used to test and verify its affinity for recombinantly expressed RBD. In addition, the neutralizing activity was tested by the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), which is designed to rapidly assess the neutralization potential of new antibodies without using natural viral particles.
Finally, IgG antibodies are expressed in the XtenCHO ™ high throughput mammalian transient system, exhibit very stable stability and consistently produce high yields.

SDS-PAGE for Anti-RBD-4 antibody

Anti-RBD-4 antibody (Casirivimab), on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Reviews

  • Toshi

    This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants(9.44 ng/mL for the wild type, 5.23 ng/mL for Alpha, >500 ng/mL for Gamma, 1.94 ng/mL for Delta).

  • Toshi

    This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants(9.44 ng/mL for the wild type, 5.23 ng/mL for Alpha, >500 ng/mL for Gamma, 1.94 ng/mL for Delta).

REVIEW YOUR PRODUCT

Add a review

Your email address will not be published. Required fields are marked *

Related products

Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control Human IgG1 LALA Isotype Control antibody (HyHEL-10) PTX17885-100 180€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.